Rapport Therapeutics

(NASDAQ) RAPP

Current Price$36.09

Market Cap$1.73B

Since IPO (2024)+74%

5 YearN/A

1 Year+193%

1 Month-3%

Rapport Therapeutics Financials at a Glance

Market Cap

$1.73B

Revenue (TTM)

$20.00M

Net Income (TTM)

-$107.28M

EPS (TTM)

-$2.60

P/E Ratio

-13.87

Dividend

$0.00

Beta (Volatility)

1.45 (Average)

Dividend

$0.00

Beta (Volatility)

1.45 (Average)

Price

$36.09

Volume

5,556

Open

$37.49

Price

$36.09

Volume

5,556

Open

$37.49

Previous Close

$36.09

Daily Range

$35.82 - $37.49

52-Week Range

$10.51 - $42.27

Estimated Earnings Date

Aug 6, 2026

Dividend

$0.00

Beta (Volatility)

1.45 (Average)

Price

$36.09

Volume

5,556

Open

$37.49

Previous Close

$36.09

Daily Range

$35.82 - $37.49

52-Week Range

$10.51 - $42.27

Estimated Earnings Date

Aug 6, 2026

RAPP News

Rapport Insider Sells $17.2 Million as Stock Surges 230% in a Year and Phase 3 Trials Near

Jonathan PoncianoApr 27, 2026

Is Rapport Therapeutics Stock a Buy After Investment Firm Cormorant Raised Its Stake Over $60 Million?

Robert IzquierdoDec 22, 2025

Rapport (RAPP) Q2 Net Loss Widens 47%

Motley Fool Markets TeamAug 7, 2025

RAPP: Motley Fool Moneyball Superscore

Our CEO Is Handing Members His Secret Weapon

It's called Motley Fool Moneyball, our new proprietary AI tool

We spent over half a million dollars in R&D to build a tool that makes stock research faster, sharper, and smarter. Our analysts use it every day, and now, you can too.

Get Access Now

About Rapport Therapeutics

Industry

Pharmaceuticals

Sector

Health Care

Employees

CEO

Abraham N. Ceesay, MBA

Website

www.rapportrx.com

Headquarters

Boston, DE, US

RAPP Financials

Key Financial Metrics (TTM)

Gross Margin

98%

Operating Margin

-6%

Net Income Margin

-5%

Return on Equity

-28%

Return on Capital

-25%

Return on Assets

-22%

Earnings Yield

-7.21%

Dividend Yield

0.00%

Payout Ratio

0.00%

Stock Overview

Market Cap

$1.73B

Shares Outstanding

47.83M

Volume

5.56K

Avg. Volume

336.60K

Financials (TTM)

Gross Profit

-$1.02M

Operating Income

-$125.10M

EBITDA

-$124.08M

Operating Cash Flow

-$87.47M

Capital Expenditure

-$616.00K

Free Cash Flow

-$88.09M

Cash & ST Invst.

$490.54M

Total Debt

$11.48M

Rapport Therapeutics Performance Analysis

Revenue Growth Rate

Annual and quarterly growth comparison

Currently no data to display.

Earnings Per Share Growth Rate

Annual and quarterly EPS growth comparison

Quarterly Performance

Name

Q1 2026YOY CHG

Revenue

$20.00M

N/A

Gross Profit

$19.77M

N/A

Gross Margin

98.87%

N/A

Market Cap

$1.73B

N/A

Market Cap/Employee

$25.02M

N/A

Employees

N/A

Net Income

-$19.86M

+17.5%

EBITDA

-$23.99M

+10.7%

Quarterly Fundamentals

Name

Q1 2026YOY CHG

Net Cash

$465.98M

+67.9%

Accounts Receivable

$58.00K

N/A

Inventory

$0.00

N/A

Long Term Debt

$8.19M

+19.8%

Short Term Debt

$2.62M

+159.4%

Return on Assets

-21.56%

N/A

Return on Invested Capital

-25.48%

N/A

Free Cash Flow

-$13.15M

+36.0%

Operating Cash Flow

-$13.06M

+35.5%

Other Investments to Explore

People Also Watch

SymbolSymbol / CompanyCompanyPricePrice Chg

KODKodiak Sciences Inc.

KODKodiak Sciences Inc.$31.05-9.10%

SEPNSepterna, Inc.

SEPNSepterna, Inc.$31.15-0.70%

URGNUroGen Pharma Ltd.

URGNUroGen Pharma Ltd.$26.85-2.72%

ANABAnaptysBio, Inc.

ANABAnaptysBio, Inc.$50.37-2.52%

NRIXNurix Therapeutics, Inc.

NRIXNurix Therapeutics, Inc.$14.64-4.19%

XNCRXencor, Inc.

XNCRXencor, Inc.$11.77-2.00%

PHATPhathom Pharmaceuticals, Inc.

PHATPhathom Pharmaceuticals, Inc.$10.13+2.74%

Trending Stocks

SymbolSymbol / CompanyCompanyPricePrice Chg

NOKNokia

NOKNokia$14.38-0.13%

TQQQProShares Trust - ProShares UltraPro Qqq

TQQQProShares Trust - ProShares UltraPro Qqq$73.05-0.14%

KEELKeel Infrastructure

KEELKeel Infrastructure$5.13-0.13%

SQQQProShares Trust - ProShares UltraPro Short Qqq

SQQQProShares Trust - ProShares UltraPro Short Qqq$43.19+0.14%

IBITiShares Bitcoin Trust

IBITiShares Bitcoin Trust$34.14-0.05%

AALAmerican Airlines Group

AALAmerican Airlines Group$13.50+0.02%

QQQInvesco QQQ Trust

QQQInvesco QQQ Trust$705.06-0.05%

Questions About RAPP

What is the current price of Rapport Therapeutics?

Rapport Therapeutics is trading at $36.09 per share.

What is the 52-week range for Rapport Therapeutics?

Over the past 52 weeks, Rapport Therapeutics has traded between $10.51 and $42.27.

How much debt does Rapport Therapeutics have?

As of the most recent reporting period, Rapport Therapeutics reported total debt of $10.80M.

How much cash does Rapport Therapeutics have on hand?

Rapport Therapeutics reported $78.16M in cash and cash equivalents in its most recent financial results.

What is Rapport Therapeutics’s dividend yield?

Rapport Therapeutics does not currently have a dividend yield.

Rapport Therapeutics

Rapport Therapeutics Financials at a Glance

RAPP News

Rapport Insider Sells $17.2 Million as Stock Surges 230% in a Year and Phase 3 Trials Near

Is Rapport Therapeutics Stock a Buy After Investment Firm Cormorant Raised Its Stake Over $60 Million?

Rapport (RAPP) Q2 Net Loss Widens 47%

RAPP: Motley Fool Moneyball Superscore

Our CEO Is Handing Members His Secret Weapon

About Rapport Therapeutics

RAPP Financials

Key Financial Metrics (TTM)

Stock Overview

Financials (TTM)

Rapport Therapeutics Performance Analysis

Revenue Growth Rate

Earnings Per Share Growth Rate

Quarterly Performance

Quarterly Fundamentals

Other Investments to Explore

People Also Watch

Trending Stocks

Questions About RAPP

What is the current price of Rapport Therapeutics?

What is the 52-week range for Rapport Therapeutics?

How much debt does Rapport Therapeutics have?

How much cash does Rapport Therapeutics have on hand?

What is Rapport Therapeutics’s dividend yield?

Premium Investing Services